Epigenic Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $92M
Overview
Developing next-generation epigenetic therapies to treat resistant cancers by reprogramming gene expression.
OncologyGenetics & Genomics
Technology Platform
A proprietary platform for the discovery of small molecule inhibitors targeting epigenetic regulatory proteins to reprogram cancer cell gene expression and overcome therapy resistance.
Funding History
2Total raised:$92M
Venture$60M
Series A$32M
Opportunities
Potential to create new combination regimens that overcome resistance to checkpoint inhibitors and targeted therapies.
Risk Factors
High risk of clinical failure due to the complexity of epigenetic biology and potential for off-target toxicities.
Competitive Landscape
Competes in a crowded but growing epigenetic drug space against both large pharma and biotech, requiring highly differentiated mechanisms and strong biomarker strategies.